SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (119)11/11/2003 2:47:58 PM
From: rkrw  Read Replies (1) | Respond to of 411
 
You still have a good memory :-)

2001 10K report...

In February 2000, Biogen announced that it had successfully completed a Phase II trial of CVT-124 in patients with moderate-to-severe CHF. However, Biogen also announced its intention to continue the AdentriTM program with a new molecule. Biogen is currently in Phase II clinical trials with the new molecule.